New research suggests that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who halt traditional diet and exercise plans.
Research printed in a major medical journal demonstrates that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"People buying such treatments need to be informed of the potential of fast weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight in about 18 months.
Analyzing Therapies
The study, which reviewed 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
The team note that individuals who shed pounds through lifestyle changes alone typically experience a less rapid creep back—around 0.1 kg a month—post-intervention.
Explaining the Fast Rebound
Doctors suggest the mechanism of the injections accounts for the accelerated rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the significant potential of relapse, the treatment might need to be life-long.
This view is echoed by pharmaceutical companies, who say that the findings "emphasize the chronic nature of excess weight," akin to managing diseases like high blood pressure.
User Experiences
Users who have stopped the medication describe a sudden resurgence of appetite.
"I experienced a switch that goes on and you're instantly extremely hungry," recalled one woman.
This difficulty is compounded if patients have not adopted permanent dietary or behavioural modifications during treatment.
Significant Adoption
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while these medications are potent agents for weight loss, they are not a permanent cure and lasting health benefits hinges on ongoing lifestyle support.
